Stacpoole Ref Rencs Agency for Toxic Substances and Disease Registry. 1997. Toxic Substances Portal: Trichloroethylene (TCE). Toxicological Profile for Trichloroethylene. Atlanta, GA:Centers for Disease Control and Prevention. Available: http://www. atsdr.cdc.gov/toxprofiles/tp.asp?id=173&tid=30 [accessed 9 September 2010]. Ammini CV, Fernandez-Canon J, Shroads AL, Cornett R, Cheung J, James MO, et al. 2003. Pharmacologic or genetic abla- tion of maleylacetoacetate isomerase increases levels of toxic tyrosine catabolites in rodents. Biochem Pharmacol 66:2029–2038. Ammini CV, Stacpoole PW. 2003. Biotransformation, toxi- cology and pharmacogenomics of dichloroacetate. In: Natural Production of Organohalogen Compounds (Gribble GW, ed). Handbook of Environmental Chemistry 3/P. Berlin:Springer, 215–234. Anderson WB, Board PG, Anders MW. 2004. Glutathione trans- ferase zeta-catalyzed bioactivation of dichloroacetic acid: reaction of glyoxylate with amino acid nucleophiles. Chem Res Toxicol 17:650–662. Anderson WB, Board PG, Gargano B, Anders MW. 1999. Inactivation of glutathione transferase zeta by dichloroa- cetic acid and other fluorine-lacking alpha-haloalkanoic acids. Chem Res Toxicol 12:1144–1149. Barshop BA, Naviaux RK, McGowan KA, Levine F, Nyhan WL, Loupis-Geller A, et al. 2004. Chronic treatment of mito- chondrial disease patients with dichloroacetate. Mol Genet Metab 83:138–149. Berendzen K, Theriaque D, Shuster J, Stacpoole PW. 2006. Therapeutic potential of dichloroacetate for pyruvate dehydrogenase complex deficiency. Mitochondrion 6:126–135. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, et al. 2007. A mitochondria-K+ channel axis is suppressed in cancer and its normalization pro- motes apoptosis and inhibits cancer growth. Cancer Cell 11:37–51. Bonnet S, Michelakis ED, Porter CJ, Andrade-Navarro MA, Thébaud B, Bonnet S, et al. 2006. An abnormal mito- chondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 113:2630–2641. Bowker-Kinley MM, Davis WI, Wu P, Harris RA, Popov KM. 1998. Evidence for existence of tissue-specific regula- tion of the mammalian pyruvate dehydrogenase complex. Biochem J 329:191–196. Brüning T, Pesch B, Wiesenhütter B, Rabstein S, Lammert M, Baumuller A, et al. 2003. Renal cell cancer risk and occu- pational exposure to trichloroethylene: results of a con- secutive case–control study in Arnsberg, Germany. Am J Ind Med 43:274−285. Charbotel B, Fevotte J, Hours M, Martin JL, Bergeret A. 2006. Case–control study on renal cell cancer and occupational exposure to trichloroethylene. Part II: epidemiological aspects. Ann Occup Hyg 50:777−787. Chiu WA, Okino MS, Evans MV. 2009. Characterizing uncer- tainty and population variability in the toxicokinetics of trichloroethylene and metabolites in mice, rats, and humans using an updated database, physiologically based pharmacokinetic (PBPK) model, and Bayesian approach. Toxicol Appl Pharmacol 241:36–60. Cornett R, James MO, Henderson GN, Cheung J, Shroads AL, Stacpoole PW. 1999. Inhibition of glutathione S-transferase zeta and tyrosine metabolism by dichloroacetate: a poten- tial unifying mechanism for its altered biotransformation and toxicity. Biochem Biophys Res Commun 262:752–756. Danpure CJ. 2001. Primary hyperoxaluria. In: Metabolic and Molecular Bases of Inherited Disease. (Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, et al., eds). 8th ed. New York:McGraw-Hill, 3323–3367. Evans MV, Chiu WA, Okino MS, Cladwell JC. 2009. Development of an updated PBPK model for trichloroethylene and metabolites in mice, and its application to discern the role of oxidative metabolism in TCE-induced hepatomegaly. Toxicol Appl Pharmacol 236:329−340. Felitsyn N, McLeod C, Shroads AL, Stacpoole PW, Notterpek L. 2008. The heme precursor delta-aminolevulinate blocks peripheral myelin formation. J Neurochem 106:2068–2079. Guengerich FP. 2004. Metabolism of trichloroethylene and covalent binding of reaction products. In: Proceedings of Symposium on New Scientific Research Related to the Health Effects of Trichloroethylene, 26–27 February, 2004, Washington, DC. Available: http://cfpub.epa.gov/ncea/ cfm/recordisplay.cfm?deid=75934 [accessed 19 December 2010]. Guo X, Dixit V, Lui H, Shroads AL, Henderson AL, James MO, et al. 2006. Inhibition and recovery of rat hepatic glutathi- one S-transferase zeta and alteration of tyrosine metabo- lism following dichloroacetate treatment and withdrawal. Drug Metab Dispos 34:36–42. H e n d e r s o n G N , C u r r y S H , D e r e n d o r f H , W r i g h t E C , Stacpoole PW. 1997. Pharmacokinetics of dichloroacetate in adult patients with lactic acidosis. J Clin Pharmacol 37:416–425. IARC (International Agency for Research on Cancer). 2004. Dichloroacetic acid. IARC Monogr Eval Carcinog Risks Hum 84:359–402. James MO, Yan Z, Cornett R, Jayanti VM, Henderson GN, Davydova N, et al. 1998. Pharmacokinetics and metabo- lism of [14C]-dichloroacetate (DCA) in the male Sprague- Dawley rats: identification of glycine conjugates, including hippurate, as urinary metabolites of dichloroacetate. Drug Metab Dispos 26:1134–1143. Jia M, Coats BS, Chadha M, Frentzen B, Perez-Rodriguez J, Chadik PA, et al. 2006. Human kinetics of orally and intra- venously administered low dose 1, 2-13C-dichloroacetate. J Clin Pharmacol 46:1449–1459. Kaufmann P, Engelstad K, Wei Y, Jhung S, Sano MC, Shungu DC, et al. 2006. Dichloroacetate causes toxic neu- ropathy in MELAS: a randomized, controlled clinical trial. Neurology 66:324–330. Ketcha MM, Stevens DK, Warren DA, Bishop CT, Brashear WT. 1996. Conversion of trichloroacetic acid to dichloroacetic acid in biological samples. J Anal Toxicol 20:236−241. Lantum HB, Liebler DC, Board PG, Anders MW. 2002. Alkylation and inactivation of human glutathione transferase zeta (hGSTZ1-1) by maleylacetone and fumarylacetone. Chem Res Toxicol 15:707–716. Lash LH, Fisher JW, Lipscomb JC, Parker JC. 2000. Metabolism of trichloroethylene. Environ Health Perspect 108:177–200. Lee JH, Chung CW, Ma YC, Wang GS, Chen PC, Hwang YH, et al. 2003. Increased mortality odds ratio of male liver can- cer in a community contaminated by chlorinated hydrocar- bons in groundwater. Occup Environ Med 60:364−369. Li W, James MO, McKenzie S, Stacpoole PW. 2011. Mitochondrion is a novel site of biotransformation of dichloroacetate by glutathione transferase zeta1. J Pharmacol Exp Ther 330:87–94. Lim CE, Matthaei KI, Blackburn AC, Davis RP, Dahlstrom JE, Koina ME, et al. 2004. Mice deficient in glutathione trans- ferase zeta/maleylacetoacetate isomerase exhibit a range of pathological changes and elevated expression of alpha, mu, and pi class glutathione transferases. Am J Pathol 165:679–693. Lindberg RL, Martini R, Baumgartner M, Erne B, Borg J, Zielasek J, et al. 1999. Motor neuropathy in porphobilino- gen deaminase-deficient mice imitates the peripheral neuropathy of human acute porphyria. J Clin Invest 103:1127–1134. McMurtry MS, Bonnet S, Wu X, Dyck JR, Haromy A, Hashimoto K, et al. 2004. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95:830–840. Merdink JL, Gonzalez-Leon A, Bull RJ, Schultz IR. 1998. The extent of dichloroacetate formation from trichloroethylene, chloral hydrate, trichloroacetate, and trichloroethanol in B6C3F1 mice. Toxicol Sci 45:33−41. Michelakis ED, McMurtry MS, Wu XC, Dyck JR, Moudgil R, Hopkins TA, et al. 2002. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pul- monary hypertension in rats: role of increased expres- sion and activity of voltage-gated potassium channels. Circulation 105:244–250. Michelakis ED, Sutendra G, Dromparis P, Webster L, Harmony A, Niven E, et al. 2010. Metabolic modulation of glioblastoma with dichloroacetate. Sci Trans Med 2:31–34. Michelakis ED, Webster L, Mackey JR. 2008. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for can- cer. Br J Cancer 99:989–994. Miller JW, Uden PC. 1983. Characterization of nonvolatile aque- ous chlorination products of humic substances. Environ Sci Technol 17:150–157. Mitchell GA, Grompe M, Lambert M, Tanguay RM. 2001. Hypertyrosinemia. In: Metabolic and Molecular Bases of Inherited Disease. Volume II (Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, Vogelstein B, eds). 8th edition. New York:McGraw-Hill, 1777–1806. Obolensky A, Shukairy H, Blank V. 2003. Occurrence of haloacetic acids in ICR finished water and distribution systems. In: Information Collection Rule Analysis Data (McGuire MJ, McLain JL, Obolensky A, eds). Denver, CO:AWWA Research Foundation, 111–140. Saghir SA, Schultz IR. 2002. Low-dose pharmacokinetics and oral bioavailability of dichloroacetate in naive and GST-zeta- depleted rats. Environ Health Perspect 110:757–763. Sassa S, Kappas A. 1983. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-amin- olevulinic acid dehydratase activity by succinylacetone. J Clin Invest 71:625–634. Schultz IR, Merdink JL, Gonzalez-Leon A, Bull RJ. 2002. Dichloroacetate toxicokinetics and disruption of tyrosine catabolism in B6C3F1 mice: dose-response relationships and age as a modifying factor. Toxicology 173:229–247. Schultz IR, Shangraw RE. 2006. Effect of short-term drinking water exposure to dichloroacetate on its pharmacokinet- ics and oral bioavailability in human volunteers: a stable isotope study. Toxicol Sci 92:42–50. Scriver R, Levy H, Donlon J. 2001. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Metabolic and Molecular Bases of Inherited Disease (Scriver C, Beaudet A, Sly W, Valle D, Childs B, Kinzler K, et al., eds). 8th ed. New York:McGraw-Hill, 1667–1724. Shroads AL, Guo X, Dixit V, Liu H-P, James MO, Stacpoole PW. 2008. Age-dependent metabolism of dichloroacetate in rats: possible relevance to human toxicity. J Pharmacol Exp Ther 324:1163–1171. Stacpoole PW. 1989. The pharmacology of dichloroacetate. Metabolism 38:1124–1144. Stacpoole PW, Henderson GN, Yan Z, Cornett R, James MO. 1998b. Pharmacokinetics, metabolism and toxicology of dichloroacetate. Drug Metab Rev 30:499–539. Stacpoole PW, Henderson GN, Yan Z, James MO. 1998a. Clinical pharmacology and toxicology of dichloroacetate. Environ Health Perspect 106:989–994. Stacpoole PW, Kerr DS, Barnes C, Bunch ST, Carney PR, Fennell EM, et al. 2006. A controlled clinical trial of dichlo- roacetate for treatment of congenital lactic acidosis in children. Pediatrics 117:1519–1531. Stacpoole PW, Kurtz TL, Han Z, Langaee T. 2008. Role of dichlo- roacetate in the treatment of genetic mitochondrial dis- eases. Adv Drug Deliv Rev 60:1478–1487. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, et al. 1992. A controlled clinical trial of dichloroacetate treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med 327:1564–1569. Sugden MC, Holness MJ. 2003. Recent advances in mech- anisms regulating glucose oxidation at the level of the pyruvate dehydrogenase complex by PDKs. Am J Physiol Endocrinol Metab 284:E855–E862. Templin MV, Stevens DK, Stenner RD, Bonate PL, Tuman D, Bull RJ. 1995. Factors affecting species differences in the kinetics of metabolites of trichloroethylene. J Toxicol Environ Health 44:435−447. Tzeng HF, Blackburn AC, Anders MW. 2000. Polymorphism- and species-dependent inactivation of glutathione transferase zeta by dichloroacetate. Chem Res Toxicol 13:231–236. U.S. Geological Survey. 2006. Volatile Organic Compounds in the Nation’s Ground Water and Drinking-Water Supply Wells. Circular 1292. Reston, VA:U.S. Geological Survey. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: the metabolic require- ments of cell proliferation. Science 324:1029–1033. 158 ovlume 119 | number 2 | February 2011 • Environmental Health Perspectives